Carotid Stenting Coverage Decision Should Discount “Flawed” European Data
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers say CMS' proposed coverage policy for carotid stenting, which includes only part of the FDA-approved indication, is based on data that do not reflect current medical practice in the United States